Cargando…
Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance.
Inhibition of protein kinase C (PKC) is discussed as a new approach for overcoming multidrug resistance (MDR) in cancer chemotherapy. For evaluation of this concept we applied the bisindolylmaleimide GF 109203X, which shows a highly selective inhibition of PKC isozymes alpha, beta 1, beta 2, gamma,...
Autores principales: | Gekeler, V., Boer, R., Uberall, F., Ise, W., Schubert, C., Utz, I., Hofmann, J., Sanders, K. H., Schächtele, C., Klemm, K., Grunicke, H. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1996
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074754/ https://www.ncbi.nlm.nih.gov/pubmed/8826855 |
Ejemplares similares
-
Bisindolylmaleimides New Ligands of CaM Protein
por: Sosa-Peinado, Alejandro, et al.
Publicado: (2022) -
Formulation of Liver-Specific PLGA-DY-635 Nanoparticles Loaded with the Protein Kinase C Inhibitor Bisindolylmaleimide I
por: Shkodra, Blerina, et al.
Publicado: (2020) -
YQ36: A Novel Bisindolylmaleimide Analogue Induces KB/VCR Cell Death
por: Cao, Ji, et al.
Publicado: (2009) -
Chloramidine/Bisindolylmaleimide-I-Mediated Inhibition of Exosome and Microvesicle Release and Enhanced Efficacy of Cancer Chemotherapy
por: Kosgodage, Uchini S., et al.
Publicado: (2017) -
Identification of Bisindolylmaleimide IX as a potential agent to treat drug-resistant BCR-ABL positive leukemia
por: Zhang, Xin, et al.
Publicado: (2016)